NL-OMON24955招募中不适用
Chemopreventive effects of 5-ASA and UDCA in Ulcerative Colitis: A Double-blind, Randomized Placebo-controlled Pilot Study.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 45
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Clinical activity index ¡Ü 4;
- •2. Long-standing extensive ulcerative colitis for more than 8 years;
排除标准
- •1. Dysplasia or colorectal cancer before study entry;
- •2. Coexistent liver disease (Primary Sclerosing Cholangitis (PSC), chronic hepatitis B or C infection);
研究者
相似试验
进行中（未招募）
不适用
Chemopreventive effects of 5-ASA and UDCA in Ulcerative Colitis:A Double-blind, Randomized Placebo-controlled Pilot Study - CRC chemoprevention in UClcerative Colitis and the risk of developing colorectal cancer.MedDRA version: 13.1Level: PTClassification code 10021972Term: Inflammatory bowel diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2009-010921-38-NLMC Utrecht
已完成
2 期
Chemopreventive effects of 5-ASA and UDCA in Ulcerative Colitis: A Double-blind, Randomized Placebo-controlled Pilot StudyInflammatory bowel disease1001796910017991Ulcerative ColitisNL-OMON36920niversitair Medisch Centrum Utrecht45
撤回
2 期
Chemopreventive effects of 5-ASA and UDCA in Ulcerative Colitis: A Double-blind, Randomized Placebo-controlled Pilot Studyulcerative colitisNL-OMON31889niversitair Medisch Centrum Utrecht45
已完成
1 期
Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing CholangitisCholangitis, SclerosingNCT01456468Yale University19
尚未招募
不适用
Persistence of oral 5-ASA treatment in ulcerative colitis.lcerative ColitisJPRN-UMIN000048318MOCHIDA PHARMACEUTICAL CO., LTD.4,400